Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: A multicentre, open-label, Australian study

Nephrology

Volumn 12, Issue 1, 2007, Pages 95-101

  Disney, Alex ^a   Jersey, Peter De ^b   Kirkland, Geoff ^c   Mantha, Murty ^d   Charlesworth, John A ^e   Gallagher, Martin ^f   Harris, David ^g   Gock, Hilton ^h   Mangos, George J ⁱ   MacMillan, Jamie ^j   Liu, Wei ^k   Viswalingam, Ajit ^l  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

^c ROYAL HOBART HOSPITAL   (Australia)

^d CAIRNS BASE HOSPITAL   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f CANBERRA HOSPITAL   (Australia)

^g WESTMEAD HOSPITAL   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j Amgen Australia   (Australia)

^k AMGEN INC   (United States)

^l Amgen Australia   (Australia)

more..

Author keywords

Anaemia; Chronic; Clinical trial; Darbepoetin alfa; Kidney failure

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BIOASSAY; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIALYSIS; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; EVALUATION; FATIGUE; FEVER; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HEMOGLOBIN DETERMINATION; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPOTENSION; INFESTATION; LETHARGY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; PERIPHERAL EDEMA; PRIORITY JOURNAL; THORAX PAIN; TREATMENT WITHDRAWAL; UREMIA; URINARY TRACT INFECTION;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; AUSTRALIA; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33846987897     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00757.x     Document Type: Article

References (30)

1. Chadban SJ, Briganti EM, Kerr PG et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J. Am. Soc. Nephrol. 2003; 14: S131-8.
2. Kazmi WH, Kausz AT, Khan SS et al. Anemia: An early complication of chronic renal insufficiency. Am. J. Kidney Dis. 2001; 38: 803-12.
3. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J. Am. Soc. Nephrol. 2002; 13: 504-10.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-305.
5. Al-Ahmad A, Rand WM, Manjunath G et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 2001; 38: 955-62.
6. Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: Results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J. Am. Soc. Nephrol. 2003; 14: 2919-25.
7. Levin A, Thompson CR. Left ventricular mass index increase in early kidney disease: Impact of decline in hemoglobin. Am. J. Kidney Dis. 1999; 34: 125-34.
8. Weiner DE, Tighiouart H, Stark PC et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am. J. Kidney Dis. 2004; 44: 198-206.
9. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch. Intern. Med. 2004; 164: 659-63.
10. Revicki DA, Brown RE, Feeny DH et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am. J. Kidney Dis. 1995; 25: 548-54.
11. Perlman RL, Finkelstein FO, Liu L et al. Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the Renal Research Institute-CKD study. Am. J. Kidney Dis. 2005; 45: 658-66.
12. Tong EM, Nissenson AR. Erythropoietin and anemia. Semin. Nephrol. 2001; 21: 190-203.
13. Obrador GT, Pereira BJ. Anaemia of chronic kidney disease: An under-recognized and under-treated problem. Nephrol. Dial. Transplant. 2002; 17 (Suppl. 11): 44-6.
14. Macdougall IC. Novel erythropoiesis stimulating protein. Semin. Nephrol. 2000; 20: 375-81.
15. Egrie J, Browne J. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol. Dial. Transplant. 2001; 16 (Suppl. 3): 3-13.
16. Elliott S, Lorenzini T, Asher S et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol. 2003; 21: 414-21.
17. Locatelli F, Olivares J, Walker R et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 2001; 60: 741-7.
18. Suranyi MG, Lindberg JS, Navarro J, Elias C, Brenner RM, Walker R. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am. J. Nephrol. 2003; 23: 106-11.
19. Toto RD, Pichette V, Navarro J et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am. J. Nephrol. 2004; 24: 453-60.
20. Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: Results from simplify the treatment of anemia with Aranesp (STAAR). Am. J. Nephrol. 2006; 26: 149-56.
21. Hertel J, Locay H, Scarlata D, Prathikanti R, Audhya P. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease. Mayo Clin. Proc. 2006; 81: 1188-94.
22. Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin. Nephrol. 2005; 63: 327-34.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley and Sons, 1973.
25. NKF-KDOQI. NKF KDOQI clinical practice guidelines for the treatment of chronic kidney failure. Am. J. Kidney Dis. 1997; 30: S192-S240.
26. AKF/ANZSN. The CARI Guidelines - Caring for Australians with Renal Impairment.2003. [Cited February 2005.] Available from URL: http://www.kidney.org.au/cari/index.htm
27. Sarac E, Veres Z, Tallam S, Barton D, Gemmel D. Hemoglobin responses following de novo darbepoetin alfa (ARANESP®) versus epoetin alfa (PROCRIT®) administration in anemic chronic kidney disease patients [abstract]. American Society of Nephrology 37th Annual Meeting & Scientific Exposition, St Louis, MO; 2004.
28. Amgen Inc. Aranesp (darbepoetin alfa) Summary of Product Characteristics (Annex I). Thousand Oaks, CA: Amgen Inc., 2004.
29. Hoggard J, Crouch T, McMurray S et al. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Curr. Med. Res. Opin. 2006; 22: 2023-30.
30. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.